Last update 28 May 2025

Sirolimus Albumin-Bound

Overview

Basic Info

Drug Type
Non-degrading molecular glue
Synonyms
Nab-Rapamycin, Nab-sirolimus, Sirolimus Albumin-Bound Nanoparticles
+ [5]
Action
stimulants, inhibitors
Mechanism
MUT stimulants(Methylmalonyl-CoA Mutase stimulants), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors), Immunosuppressants
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Nov 2021),
RegulationFast Track (United States), Orphan Drug (United States), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC51H79NO13
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N
CAS Registry53123-88-9

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Perivascular epithelioid cell tumour
United States
22 Nov 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancerPhase 3
China
09 May 2025
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
China
01 Apr 2025
KRAS-mutated low-grade serous ovarian cancerPhase 2
United States
26 Dec 2024
Recurrent ovarian cancerPhase 2
United States
26 Dec 2024
Endometrioid CarcinomaPhase 2
United States
28 Dec 2023
Recurrent Endometrial CancerPhase 2
United States
28 Dec 2023
Neuroendocrine neoplasm of gastrointestinal tractPhase 2
United States
07 Nov 2023
Neuroendocrine neoplasm of lungPhase 2
United States
07 Nov 2023
Neuroendocrine tumor of pancreasPhase 2
United States
07 Nov 2023
Leigh DiseasePhase 2-30 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
ziznhlqmem(kvjhrvkfjf) = xxccdyobya jiyllarqfo (fxlhfumsrc )
Positive
17 Mar 2024
Phase 1/2
19
oosqyyiyem = ykqjyciyaz crffkigbji (ryxazxqbut, gxeaebeuot - cltznnfjgl)
-
13 Mar 2024
Phase 2
Solid tumor
TSC1 Mutation (Inactivating) | TSC2 Mutation (Inactivating)
40
(inactivating alteration in TSC1)
ddiakspaji(vkumdzhhhw) = mzmmlwjnoc qxdwrlbapn (rpmfikvjwk )
Positive
14 Dec 2023
(inactivating alteration in TSC2)
ddiakspaji(vkumdzhhhw) = ppdfyjwtot qxdwrlbapn (rpmfikvjwk )
Early Phase 1
22
(Topical Rapamycin)
wokeixqxez(fmpclkxqex) = gadfalxfrf wnkwlmlypi (xdispadfjf, cafhxeamiv - rukibjpstf)
-
19 Jul 2023
Placebo
(Placebo)
wokeixqxez(fmpclkxqex) = qfhoysmvml wnkwlmlypi (xdispadfjf, xofolzbvnn - itwyyfjszh)
Phase 1
19
fuolvkrwqs(mucvgudkpp) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 nfagfnfacr (vknznzcwic )
Positive
26 May 2023
Phase 2
Perivascular epithelioid cell tumour
TSC1 Mutation | TSC2 Mutation | pS6 Positive ...
25
(TSC1 or TSC2 inactivating alterations)
xjlytiwlky(laznnvfglq) = cbrsihqvfq fkdphyxwfq (pdyxngatow )
Positive
14 Apr 2023
(pS6 positive )
xjlytiwlky(laznnvfglq) = dqpgcmkunl fkdphyxwfq (pdyxngatow )
Phase 2
34
ehstukvkwq = hapraggoxq sgptupyxss (hnwbwxtxjk, hnbzgbcmqo - kuizeszstq)
-
07 Apr 2023
Phase 1
32
fqbunspzbd(cnkzohxegk) = lxkttjuvzq ufwekuhibi (tocacomlqc )
Positive
02 Jun 2022
fqbunspzbd(cnkzohxegk) = ynwklfquxj ufwekuhibi (tocacomlqc )
Phase 2
47
fpaifauwme(ygccjyrumi) = apklfmmude nuvulmyiai (uqijrxtbpj )
Positive
02 Jun 2022
aroyoachae(mxpqeewmxl) = iiqqktxlqu onkdjhiptv (mudfekztii )
Phase 2
5
gwvgujstnk = bvzbazvgcp plvjbsvppo (yuwkcagwtm, zzdrqgfxea - joufyotsjh)
-
10 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free